Bayer launches vericiguat in India to reduce frequent hospitalisations, risk of death in worsening HF patients https://ift.tt/6AFCDu3

Verquvo will be made available to address the needs of HF patients in India at an India-specific price, almost at the same time as HF patients around the world. Bayer has received approval of vericiguat (Verquvo) in India based on the results of the pivotal Phase III VICTORIA trial, published in The New England Journal of Medicine (NEJM) in March 2020.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/lhZmkR1